Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

• Status: Unknown status
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to assess the biodistribution and kinetics of a novel T-cell imaging agent in non-small cell lung cancer patients undergoing immunotherapy with and without adjuvant radiation therapy. This study is assessing the change in kinetics that occurs in this patient population to better understand the distribution of this compound in patient disease circumstances.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Tennessee
• Collaborator: CellSight Technologies, Inc.
• Treatments: Immunologic Factors

Criteria

Inclusion Criteria:

• This study is open to all adult subjects with histological confirmation of NSCLC enrolled in the parent protocol.

• Age 21 years of age or greater

• ECOG performance status of 0, 1, 2 or 3 at the time of enrollment.

• Patient with life expectancy ≥ 24 weeks from the time of screening to the study

• Ability to give informed consent

Exclusion Criteria:

• Patients with severe claustrophobia (patients with milder forms of claustrophobia that can be successfully allayed with oral anxiolytic therapy are allowed).

• Severe impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73 m2 and/or on dialysis.

• Pregnancy

• Breast Feeding an infant

• Unable to tolerate the expected radiation therapy prescription